Cytosorbents Corp. (CTSO)
Cytosorbents Corp. is a biomedical company specializing in the development and commercialization of blood purification technologies. Its flagship product, Cytosorb, is an innovative blood filter designed to remove toxins, inflammatory mediators, and other harmful substances from the bloodstream. The company focuses on applications in critical care, such as sepsis, trauma, and various inflammatory conditions, aiming to improve patient outcomes through its blood purification solutions.
Company News
CytoSorbents reported a 3% decrease in Q1 2025 revenue, but improved operating loss and net loss. The company is making progress with its DrugSorb-ATR device, which is under review by the FDA and Health Canada.
CytoSorbents Corporation reported strong preliminary Q4 2024 financial results, with product revenue growth estimated at 22-25% year-over-year and gross margin improving to around 70%. The company also provided updates on its regulatory progress for DrugSorb-ATR, an investigational device to reduce perioperative bleeding in CABG surgery patients.
CytoSorbents (CTSO) delivered earnings and revenue surprises of -78.57% and 11.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Insiders are buying these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The biotech company took another step toward introducing a new way of performing bypass surgeries.